Overview
The TDB of the DST, under the Ministry of Science & Technology, has approved financial support for M/s Bioneemtec India Private Limited, Chennai. The project, titled “Manufacturing of Minoxidil, Tranexamic Acid, Dequalinium Chloride, their Intermediates and Drug Liposomes,” aims to commercialise indigenous green chemistry technologies for pharmaceutical manufacturing.
Key Developments
- Establishment of batch and continuous‑flow chemistry units to produce critical API intermediates, APIs and liposomal drug delivery systems.
- Commercialisation of an indigenous, cost‑effective synthesis route for Tranexamic Acid, a drug used in bleeding disorders.
- Domestic scale‑up of Minoxidil (hair‑loss treatment) and Dequalinium Chloride (antimicrobial agent) along with their key intermediates.
- Development of proprietary drug liposome APIs using advanced nanotechnology for potential cancer therapy.
- Initiation of intellectual‑property protection to secure the novel technologies.
Important Facts
The project targets three strategic outcomes: (i) import substitution by reducing reliance on imported pharmaceutical intermediates, (ii) sustainable manufacturing through waste‑minimising green chemistry, and (iii) enhanced healthcare security via indigenous production of critical drugs. The technology combines modern process engineering with nanotechnology, promising higher yields, better product quality, and improved occupational safety.
UPSC Relevance
Understanding this initiative helps aspirants in several GS papers:
- GS 3 – Economy & Science & Technology: Role of TDB in fostering high‑tech industries and reducing trade deficits.
- GS 4 – Ethics & Governance: The emphasis on environmentally responsible manufacturing aligns with sustainable development goals.
- GS 1 – Indian Polity: Illustrates how central ministries coordinate to translate research into commercial outcomes.
Way Forward
To maximise impact, the following steps are recommended:
- Scale‑up pilot plants to full commercial capacity while monitoring environmental metrics.
- Encourage collaborations between academia, research institutes and industry for continuous‑flow and nanotech advancements.
- Strengthen IP frameworks to protect home‑grown innovations and attract foreign investment.
- Integrate these indigenous APIs into national health programmes to ensure affordable drug supply.
Overall, the initiative showcases India’s push towards self‑reliant, green pharmaceutical manufacturing, a priority area for future policymakers.